Antonio Sahuquillo-Torralba

Antonio Sahuquillo-Torralba

Auto-generated profile, based on publicly available information

Antonio Sahuquillo-Torralba

Hospital Universitario y Politécnico La Fe, Valencia, España

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2020 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
MGMarta Garrido-Jareño
Marta Garrido-Jareño
ASAntonio Sahuquillo-Torralba
Antonio Sahuquillo-Torralba
RCRabab Chouman-Arcas
Rabab Chouman-Arcas
ICIván Castro
Iván Castro
JMJosé Miguel Molina-Moreno
José Miguel Molina-Moreno
JPJavier Pemán
Javier Pemán
Background: Leishmaniasis, considered by the World Health Organization as one of the most important tropical diseases, is endemic in the Mediterranean Basin. The aim of this study was to evaluate epidemiological and clinical characteristics of cutaneous (CL) and mucocutaneous leishmaniasis (MCL) in La Fe University Hospital, Valencia, Spain. The particular focus was on diagnosis techniques and clinical differences according to the immunological status of the patients. Methods: An eleven-year retrospective observational study of CL and MCL episodes at the hospital was performed. Epidemiological, clinical and therapeutic variables of each case, together with the microbiological and anatomopathological diagnosis, were analyzed. Results: A total of 42 patients were included, 30 of them were male and 28 were immunocompetent. Most of the cases (36/42) were diagnosed in the last 5 years (2013–2017). The incidence of CL and MCL increased from 3.6/100,000 (2006–2012) to 13.58/100,000 (2013–2017). The majority of the patients (37/42) exhibited CL, in 30 cases as single lesions (30/37). Ulcerative lesions were more common in immunosuppressed patients (13/14) than in immunocompetent patients (20/28), (P = 0.2302). The length of lesion presence before diagnosis was 7.36 ± 6.72 months in immunocompetent patients and 8.79 ± 6.9 months in immunosuppressed patients (P = 0.1863). Leishmania DNA detection (92.3%) was the most sensitive diagnostic technique followed by Giemsa stain (65%) and histopathological examination (53.8%). Twelve patients (12/42) had close contact with dogs or were living near to kennels, and 10 of them did not present underlying conditions. Intralesional glucantime (21/42) and liposomal amphotericin B (7/42) were the most common treatments administered in monotherapy. All patients evolved successfully and no relapse was reported. Conclusions: Some interesting clinical and epidemiological differences were found in our series between immunocompetent and immunosuppressed patients. Future studies can take these results further especially by studying patients with biological therapy. Skin biopsies combining NAAT with histological techniques are the most productive techniques for CL or MCL diagnosis.

4 January 2021 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
CHC Hernández-Fernández
C Hernández-Fernández
GCG Carretero
G Carretero
RRR Rivera
R Rivera
CFCarlos Ferrándiz
Carlos Ferrándiz
EDEsteban Dauden
Esteban Dauden
AGa Group
a Group
The effect of gender on systemic therapy for psoriasis has not been well studied. The aim of this st...

9 April 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
EAElena del Alcázar
Elena del Alcázar
JSJorge A. Suárez‐Pérez
Jorge A. Suárez‐Pérez
Susana ArmestoSusana Armesto
Susana Armesto
RRRaquel Rivera
Raquel Rivera
EHEnrique Herrera‐Acosta
Enrique Herrera‐Acosta
JCJosé Manuel Carrascosa
José Manuel Carrascosa

24 November 2021 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
EAElena del Alcázar
Elena del Alcázar
ALAnna López López-Ferrer
Anna López López-Ferrer
ÁMÁlvaro Martínez‐Doménech
Álvaro Martínez‐Doménech
Ricardo Ruiz-VillaverdeRicardo Ruiz-Villaverde
Ricardo Ruiz-Villaverde
MLMar Llamas-Velasco
Mar Llamas-Velasco
José Manuel CarrascosaJosé Manuel Carrascosa
José Manuel Carrascosa
Background Data on the effectiveness and safety of a drug in real-world clinical practice complement the evidence from clinical trials, which are carried out in a different setting. Little has been published on the effectiveness and safety of guselkumab in the treatment of psoriasis in clinical practice. Objectives To assess the effectiveness and safety of guselkumab at 24 weeks in patients with moderate to severe plaque psoriasis in routine clinical practice. Methods Retrospective, multicentre study of adult patients with moderate to severe plaque psoriasis treated with guselkumab for at least 24 weeks in Spain. Results We studied 343 patients, 249 of whom were followed for 24 weeks. By week 24, the mean (SD) Psoriasis Area and Severity Index (PASI) had decreased from 11.1 (7.3) to 1.7 (2.8) (-9.3; [-10.2;-8.4]), 85.9% of the patients had achieved PASI score of 4 or less and 77.9% a PASI score of 2 or less. In terms of relative PASI response, 59.4% of the patients achieved a PASI-90 response and 49.0% a PASI-100 response. On multivariate analysis, 2 factors reduced the probability of a PASI of 2 or less at 24 weeks: a BMI ≥30 (OR, 0.44; 95% CI, 0.22-0.88) and a greater previous exposure to biologic therapy (OR, 0.69; 95% CI, 0.56-0.84]). Adverse events were rare (9.9%) and led to withdrawal from treatment in only 9 patients (2.6%) by the end of the follow-up period. Conclusion The results of this study confirm the high efficacy and safety of guselkumab indicated by the clinical trial data. In clinical practice, the absolute PASI score appears to be a better marker of response to treatment than the relative value.

1 April 2016 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Closed access
ASA. Sahuquillo-Torralba
A. Sahuquillo-Torralba
RBR. Ballester-Sánchez
R. Ballester-Sánchez
CPC. Pujol-Marco
C. Pujol-Marco
RBR. Botella-Estrada
R. Botella-Estrada

1 August 2019 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
JOJosé-María Ortiz-Salvador
José-María Ortiz-Salvador
MSMartina Saneleuterio-Temporal
Martina Saneleuterio-Temporal
JMJorge Magdaleno-Tapial
Jorge Magdaleno-Tapial
MVManel Velasco-Pastor
Manel Velasco-Pastor
CPConrad Pujol-Marco
Conrad Pujol-Marco
APAmparo Pérez-Ferriols
Amparo Pérez-Ferriols
Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in phase 3 studies. To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiologic characteristics of patients treated with secukinumab in clinical settings. In this multicenter prospective observational study, we recruited adult patients with moderate-to-severe plaque psoriasis from 12 hospitals in Spain during January-December 2016. These patients were treated with secukinumab and prospectively followed at 12-week intervals for 52 weeks. In total, 158 patients were recruited to the study. A Psoriasis Area and Severity Index (PASI) score improvement ≥75% over baseline (PASI-75) was achieved by 57%, 83.5%, 89%, and 78.5% of patients at weeks 4, 12, 24, and 52, respectively. PASI-90 was achieved in 27.8%, 62%, 64.6%, and 63.2% of patients at weeks 4, 12, 24, and 52, respectively; PASI-75 and PASI-90 responders were significantly more common among patients with a body mass index <30 kg/cm2 and patients without previous biologic therapy failures. Observational study. Time from onset of psoriasis was not evaluated. Secukinumab is a safe treatment with effectiveness rates similar to those found in its phase 3 studies. These rates endure up to a year from start of treatment.